Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NEURA Robotics Announces Record Series C of up to $1.4 Billion to Accelerate the World’s Leading Physical AI Platform10.6.2026 18:26:00 EEST | Press release
NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure, including Tether, Qualcomm Technologies, Inc., Amazon, NVIDIA, imec.xpand, Bosch, Schaeffler, European Investment Bank, Lingotto Horizon, InterAlpen Partners and others. NEURA is building a new category of AI infrastructure where cognitive robots continuously learn, collaborate and operate across real world environments through a shared intelligence ecosystem called the Neuraverse. Unlike traditional robotics companies focused on isolated machines or narrow industrial automation, NEURA combines robotics, AI, sensors, edge compute and large scale learning infrastructure into one unified platform architecture de
ees Europe: Green Hydrogen: Opportunities and Production Ramp Up10.6.2026 17:13:00 EEST | Press release
For the major economies, the transformation towards a climate-neutral industry is one of the central tasks for the coming decades. While the European Union has pledged climate neutrality by 2050, China’s goal is to be climate-neutral by 2060. Hydrogen is a key to transforming their manufacturing and energy industry. However, the actual market development is lagging behind these ambitious objectives: According to the Global Energy Report 2025, only 11 percent of hydrogen projects announced since the start of the decade are now in operation or have been secured by investment decisions. This is why ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, is putting a spotlight on hydrogen. The newly aligned exhibition segment Hydrogen Dialogue Forum & Expo in hall B2 will be giving in-depth information about the opportunities for hydrogen technology, technological innovation, savings potential and ground-breaking projects from June 23–25. Th
Info-Tech Research Group Recognizes Laserfiche as a Champion in the 2026 Enterprise Content Management – Enterprise Emotional Footprint Report10.6.2026 17:00:00 EEST | Press release
Laserfiche has been named a Champion for the enterprise category in the Enterprise Content Management Emotional Footprint 2026 Report by Info-Tech Research Group. Laserfiche — the leading SaaS provider of intelligent content management — was recognized based on reviews provided by end users. Laserfiche was recognized as a Champion for delivering significant business value, continued product innovation, and strong customer experience. “We are honored to be named a Champion by Info-Tech Research Group, which we believe underscores our relationships with our customers and commitment to their long-term success,” said Thomas Phelps, CIO and SVP of corporate strategy at Laserfiche. “We are grateful to our customers for partnering with us as we support their needs for AI-driven information management solutions. Of the 285 customers who completed an Info-Tech survey this year, 99% said they plan to renew.” Info-Tech Research Group’s Emotional Footprint report quantifies the end-user experience
BTG Pactual TIG Acquires Jamestown’s Timberland Platform10.6.2026 16:30:00 EEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, today announced the acquisition of approximately 90,000 acres of U.S. timberland formerly managed by Jamestown, a global design-focused real estate investment and management firm. The Jamestown timberland platform will be integrated into BTG Pactual TIG’s core U.S. timberland strategy’s portfolio. The portfolio of high-quality timberland spans five U.S. states, including approximately 50,000 acres of pine timberland in Georgia and Alabama and approximately 40,000 acres of diversified hardwood timberland across Indiana, Pennsylvania, and New York. All properties are certified under the Sustainable Forestry Initiative (SFI). The acquisition increases BTG Pactual TIG’s core U.S. timberland strategy’s portfolio to more than 1.7 million acres. The firm manages 3.3 million acres globally. The transaction creates further opportunities for BTG Pactual TIG to scale positive cons
Capcom’s Dragon’s Dogma 2: Dark Arisen Scheduled to Launch on October 9, 2026!10.6.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2: Dark Arisen, which includes an expansion for Dragon’s Dogma 2, is scheduled to be released on October 9, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610422753/en/ Dragon's Dogma 2: Dark Arisen logo The Dragon’s Dogma series consists of action games in a fantasy setting where players adventure in an expansive open world of swords and magic. Since the release of the first game in 2012, the series garnered praise worldwide for gameplay features such as its “pawn” adventure companions who can carry out actions on their own, leading the series to over 14 million* units sold cumulatively. Dragon’s Dogma 2: Dark Arisen is a paid expansion title that adds a new story to Dragon’s Dogma 2, which was released in March 2024. Based on the wide range of feedback received following the release of the main game, this expansion is being developed to offer greate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom